PMID- 31936858
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Jan 10
TI  - Efficacy of Different Chemotherapy Regimens in Patients with Locally Advanced 
      Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative 
      Concurrent Chemoradiotherapy.
LID - 10.3390/jcm9010197 [doi]
LID - 197
AB  - Esophageal squamous cell carcinoma (ESCC) and head/neck squamous cell carcinoma 
      (HNSCC) are very common cancers worldwide, and there is higher incidence of 
      synchronous ESCC/NSCC in Taiwan. The aim of the current study was to investigate 
      the efficacy of different chemotherapy regimens in patients with locally advanced 
      synchronous ESCC/HNSCC who received curative concurrent chemoradiotheapy (CCRT). 
      A total of 75 patients were identified and assigned to one of two groups: 45 
      patients receiving cisplatin/5-fluorouracil (5-FU) regime in one group and 30 
      patients receiving a weekly cisplatin regime in the other. Overall survival (OS) 
      was calculated from the date of diagnosis of the ESCC or HNSCC to the date of 
      death from any cause or the most recent follow-up. Kaplan-Meier curves and 
      log-rank tests were used to estimate OS and differences between the two groups, 
      respectively. There was no significant difference in the analysis of OS between 
      the cisplatin/5-FU and the weekly cisplatin groups. However, patients that 
      interrupted their CCRT were found to have worse OS compared to those without 
      interruptions (5.4 months versus 18.8 months, p = 0.002). In subgroup analysis, 
      patients without interruptions of CCRT had a better OS than those with 
      interruptions in the cisplatin/5-FU group (13.0 months versus 5.4 months, p = 
      0.041) as well as in the weekly cisplatin group (21.4 months versus 5.0 months, p 
      = 0.017). Interruption of CCRT was the only independently poor prognostic factor 
      of OS in the univariate and multivariate (hazard ratio 0.18, p < 0.001) analyses. 
      Most interruption of CCRT resulted from adverse events (AEs) or serious AEs. 
      Although there was no significant difference in the incidence of AEs between 
      these two groups, lower incidence of adverse events was mentioned in the weekly 
      cisplatin group. Our study suggests that interruption of CCRT is an independently 
      poor prognostic factor of OS, and that completion of CCRT without interruption is 
      more important than the choice of chemotherapeutic regimen for patients with 
      synchronous ESCC/HNSCC.
FAU - Chen, Yen-Hao
AU  - Chen YH
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, Taoyuan 333, Taiwan.
AD  - School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
FAU - Lu, Hung-I
AU  - Lu HI
AD  - Department of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial 
      Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
FAU - Chien, Chih-Yen
AU  - Chien CY
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung 833, Taiwan.
FAU - Lo, Chien-Ming
AU  - Lo CM
AD  - Department of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial 
      Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
FAU - Wang, Yu-Ming
AU  - Wang YM
AD  - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
FAU - Chou, Shang-Yu
AU  - Chou SY
AD  - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
FAU - Li, Shau-Hsuan
AU  - Li SH
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20200110
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7020070
OTO - NOTNLM
OT  - chemotherapy
OT  - concurrent chemoradiotherapy
OT  - esophageal cancer
OT  - head and neck cancer
OT  - synchronous
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2020/01/16 06:00
MHDA- 2020/01/16 06:01
PMCR- 2020/01/10
CRDT- 2020/01/16 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2019/12/15 00:00 [revised]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/01/16 06:00 [entrez]
PHST- 2020/01/16 06:00 [pubmed]
PHST- 2020/01/16 06:01 [medline]
PHST- 2020/01/10 00:00 [pmc-release]
AID - jcm9010197 [pii]
AID - jcm-09-00197 [pii]
AID - 10.3390/jcm9010197 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jan 10;9(1):197. doi: 10.3390/jcm9010197.